Steroids in Duchenne dystrophy.

نویسنده

  • V Dubowitz
چکیده

The mills of God grind slowly. The medical profession are not far behind. It is almost 40 years since Drachman et al. [1] in an open study of 14 patients with Duchenne dystrophy, aged 3–10 years, for periods ranging from 1 to 28 months, concluded that steroids might have some palliative benefit, and that further studies were needed. Some 14 years later Brooke and his colleagues [2] took up the challenge and showed in a multicentric study of 33 patients, aged 5–15 years, (12 of whom had a ready lost ambulation), a definite improvement in muscle function on 1.5 mg/kg/day of prednisone, compared with the natural history of their 170 historical controls in earlier studies. At the same time DeSilva et al. [3] showed longterm benefit in some of the original Drachman cases, using age of loss of ambulation as the only criterion for assessment. They concluded, however, that the relatively short-lived beneficial effect on the muscle strength was outweighed by the not inconsiderable side effects of prolonged steroid therapy, and did not feel able to recommend steroids as a general long-term therapy for muscular dystrophy. Brooke and his colleagues [4] then went onto a randomized, double-blind, placebo-controlled trial of 103 boys aged 5–15 years, at two dosage levels of 1.5 and 0.75 mg/kg/day, over a 6 month period and found a comparable increase in muscle strength in the two prednisone groups at 1, 2 and 3 months, after which it leveled off, whereas the control group showed a steady loss of strength similar to the natural history. When Mike Brooke reviewed their cumulative data at the International Muscle Congress in Munich in 1990 [5], I was struck by the regular increase in muscle strength after initiation of therapy, followed by a plateau, and wondered whether pulsed therapy might produce similar results and avoid the not inconsiderable side effects, which they still considered at that time a constraint on recommending the treatment [6]. I tried a schedule of 10 days of therapy at 0.75 mg/kg/ day at the beginning of each month, which I thought

برای دانلود رایگان متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

P164: Adeno-Associated Viral Vectors in Duchenne Muscular Dystrophy

Duchenne muscular dystrophy (BMD) is an inherited X-link disease. The incidence of this muscle-wasting disease is 1:5000 male live births. Mutation in the gene coding for dystrophin is the main cause of BMD. Most cases of this disease succumb to respiratory and cardiac failure in 3rd to 4th decades. The slow progression of BMD and recent achievement of gene therapies make it as an appropriate c...

متن کامل

Detection of the Duplication in Exons 56-63 of Duchenne Muscular Dystrophy Patients with MLPA

Background Duchenne Muscular Dystrophy (DMD) is a deadly X-linked recessive disorder. This genetic disorder affects 1 among 3,500-5,000 males in the world. The majority of the patients are male, due to the type of inheritance. It affects most of the skeletal, the respiratory, and cardiac muscles, causing these vital organs to contract and eventually mortality.<br...

متن کامل

Fat embolism after fractures in Duchenne muscular dystrophy: an underdiagnosed complication? A systematic review

Duchenne muscular dystrophy is the most frequent lethal genetic disease. Several clinical trials have established both the beneficial effect of steroids in Duchenne muscular dystrophy and the well-known risk of side effects associated with their daily use. For many years it has been known that steroids associated with ambulation loss lead to obesity and also damage the bone structure resulting ...

متن کامل

Effects of steroids and angiotensin converting enzyme inhibition on circumferential strain in boys with duchenne muscular dystrophy: a cross-sectional and longitudinal study utilizing cardiac magnetic resonance imaging

Effects of steroids and angiotensin converting enzyme inhibition on circumferential strain in boys with duchenne muscular dystrophy: a cross-sectional and longitudinal study utilizing cardiac magnetic resonance imaging Katelyn Williams, Kan N Hor, Wojciech Mazur, Hussein R Al-Khalidi, Eugene S Chung, Linda S Cripe, Kathi Kinnett, Michael D Taylor, Nandakishore Akula, William M Gottliebson, D Wo...

متن کامل

Steroids in Duchenne muscular dystrophy: from clinical trials to genomic research.

Steroids represent the only pharmacological palliative treatment for Duchenne muscular dystrophy. However, they do have side effects and despite a large number of published studies showing their efficacy, they are still not universally used. This is largely due to the lack of functional outcome and quality of life measures in most of the published studies and suggests that further trials might ...

متن کامل

Comparison of motor strength and function in patients with Duchenne muscular dystrophy with or without steroid therapy.

OBJECTIVE To compare muscle strength (MS) and motor function in patients with Duchenne muscular dystrophy (DMD) receiving steroids for different times against the natural evolution of DMD described by Scott et al. METHOD 90 patients with DMD (aged 5- 12 years), receiving steroids for one to seven years, were evaluated by Medical Research Council Scale (MRC) and Hammersmith motor ability score...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

عنوان ژورنال:
  • Neuromuscular disorders : NMD

دوره 23 7  شماره 

صفحات  -

تاریخ انتشار 2013